2024年9月,Therapeutic Advances in Medical Oncology发表了一篇名为“Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2- breast cancer”的综述,专门研究了HR+/HER2-乳腺癌中CDK4/6抑制剂耐药的机制,以及...
2.CDK4/6 inhibitor resistance mechanisms and treatment strategies. DOI: 10.3892/ijmm.2022.5184 3.Targeting CDK4/6 for Anticancer Therapy. Biomedicines 2022, 10, 685. doi.org/10.3390/biomedicines10030685 4.PROTACs suppression of CDK4/6, ...
2024年9月,Therapeutic Advances in Medical Oncology发表了一篇名为“Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2- breast cancer”的综述,专门研究了HR+/HER2-乳腺癌中CDK4/6抑制剂耐药的机制,以及对抗这种耐药性的前瞻性治疗方法[7]。本文梳理CDK4/6抑制剂耐药机制相关内容,以飨读者。
相信随着CDK4/6抑制剂耐药性、不良反应等问题的不断解决,未来会有更多CDK4/6抑制剂被成功研发上市,有望改写乳腺癌的治疗格局,使乳腺癌患者受益。 参考文献: 2.CDK4/6 inhibitor resistance mechanisms and treatment strategies. DOI: 10.3892/ijmm.2022.5184 5.CDK4/6 inhibitors in HER2-positive breast cancer....
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6...
Translational research efforts, such as preclinical models and biomarker studies, offer valuable insight into resistance mechanisms and may guide the identification of novel combination therapies. This review paper aims to outline the reported mechanisms underlying CDK4/6 inhibitor resistance,...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6...
2. Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C.E. Overcoming CDK4/6 Inhibitor Resistance in ER-Positive Breast Cancer. Endocr. Relat. Cancer 2019, 26, R15–R30. 3. Klein, M.E.; Kovatcheva, M.; Davis, L.E.; Tap, W.D.; Koff, A. CDK4/6...
Cai Z, Shi Q, Li Y, Jin L, Li S, Wong LL, Wang J, Jiang X, Zhu M, Lin J, Wang Q, Yang W, Liu Y, Zhang J, Gong C, Yao H, Yao Y, Liu Q. LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein. Sci Adv. 2023 Oct 6;9(40...
Wang Q, Yang W, Liu Y, Zhang J, Gong C, Yao H, Yao Y, Liu Q. LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein. Sci Adv. 2023 Oct 6;9(40):eadi3821. d...